Multi-year health insurance plans hold promise

Laura Pedulli | | Health Exec | Policy & Regulations

Multi-year insurance products on health insurance exchanges could prompt insurers to invest in more services with long-term benefits. This in turn, would reduce healthcare costs and some of those savings could result in lower premiums for consumers, according to a Health Affairs blog written by a senior scientist and policy researcher at Rand Corp.

While many challenges exist in exploring this possibility, the ability to align the interests of health plan enrollees and insurers by reaping long-term benefits of patient health management are worth exploring, they argue. 

Read more below:

Health Insurance Without An Annual Expiration Date? A Case For Exchange-Based L…

Laura Pedulli

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.